Everyone, including Linda Powers and Dr Linda Liau have been learning about the potential of the DCVax platform along the way. Opportunities that did not seem likely suddenly moved into sight. What started as a GBM treatment study turned into GBM, rGBM and likely lower grade gliomas. Then with the Specials Program patients the opportunity obviously expanded as did the high cost medicines indication for murcidencel from GBM to cancer. You can complain all you want about what was but the learning curve from 2020 will eventually come around to what now is; ). Best wishes.
Market Data 
Markets 
AI
